Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam

This study has been completed.
Information provided by (Responsible Party):
UCB Pharma Identifier:
First received: April 28, 2006
Last updated: May 24, 2012
Last verified: May 2012
Phase IV, observational, post-authorization, cross sectional, open-label, multicenter study to evaluate the acceptability of oral solution of levetiracetam in patients with partial epilepsy as assessed by a questionnaire.

Condition Intervention Phase
Drug: Levetiracetam
Phase 4

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam (Keppra®) (SOLUCION Study)

Resource links provided by NLM:

Further study details as provided by UCB Pharma:

Estimated Enrollment: 600
Study Start Date: April 2006
Study Completion Date: July 2006
Primary Completion Date: July 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Study populaton is defined. See Eligibility Criteria.

Inclusion Criteria:

  • Patients 16 years old or older diagnosed with partial epilepsy with or without generalization receiving levetiracetam oral solution for at least 28 days before the study

Exclusion Criteria:

  • Patients with disturbances of the sense of taste and smell that can interfere with the assessment of the parameters of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00319605

  Show 54 Study Locations
Sponsors and Collaborators
UCB Pharma
Study Director: Helena Marin Muñoz, MD UCB Pharma
  More Information

Responsible Party: UCB Pharma Identifier: NCT00319605     History of Changes
Other Study ID Numbers: N01242
Study First Received: April 28, 2006
Last Updated: May 24, 2012

Keywords provided by UCB Pharma:
Cross sectional study
oral solution

Additional relevant MeSH terms:
Pharmaceutical Solutions
Nootropic Agents
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs processed this record on May 22, 2017